GERN
Geron Corporation·Healthcare
1.67
5.114%(−0.09)
Market ClosedLast Updated: — ET
52W L: $1.0452W H: $2.01
GERN NEWS
globenewswire.com
5d ago
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 11:00 a.m. ET.
defenseworld.net
Mar 31
Geron (NASDAQ:GERN) Share Price Passes Above 200 Day Moving Average – What’s Next?
Geron Corporation (NASDAQ: GERN - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $1.38 and traded as high as $1.43. Geron shares last traded at $1.41, with a volume of 16,679,509 shares. Analyst Ratings Changes Several brokerages recently issued reports
globenewswire.com
Mar 26
Geron Announces Appointment of New Members to its Board of Directors
Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies Patricia S. Andrews and Constantine Chinoporos are proven industry veterans with decades of experience leading and advising biopharmaceutical companies
defenseworld.net
Mar 22
Geron Corporation (NASDAQ:GERN) Given Average Recommendation of “Hold” by Analysts
Shares of Geron Corporation (NASDAQ: GERN - Get Free Report) have been assigned an average rating of "Hold" from the seven analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and two have given a buy recommendation to the company.
seekingalpha.com
Mar 19
Geron: Minimal Sales Growth But A Potential Run-Up Ahead
Geron Corporation's Q4 '25 net product revenues of $48M are similar to those seen in Q4 '24 ($47.5M). Despite fairly flat quarterly revenues, GERN maintains 2026 net product revenue guidance of $220M-$240M, implying 25% growth. Key catalysts include a potential IMpactMF interim readout in H2 '26 and readouts from investigator-sponsored trials and potential real-world data that could encourage use of Rytelo.
globenewswire.com
Mar 18
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective March 17, 2026, it granted stock options to purchase an aggregate of 956,250 shares of common stock to six newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
